Monday, June 15, 2026

Analysis: China’s Reluctance on Denuclearization Poses Challenge for US and Its Allies

Foreign Minister Cho Hyun urges China to aid in North Korea negotiations, emphasizing cooperation for peace and economic collaboration.

North Korea Publishes Broad Height Ranges for Students Amid Furniture Standardization Drive

North Korea emphasizes educational furniture standards and average student heights, revealing discrepancies with South Korea's measurements.

North Korean Hackers Impersonates U.S. Officials in Sneaky Cyber Attack in South Korea

North Korea's Kimsuky group attempted a cyber attack in South Korea using deceptive ClickFix tactics to impersonate U.S. officials.

Tag: GERD

Onconic Therapeutics Licenses GERD Drug Zaqubo to Indonesia’s Dexa Medica

Onconic Therapeutics partners with Dexa Medica to commercialize GERD treatment Zaqubo in Indonesia, enhancing its global expansion strategy.

Large-Scale Real-World Study Supports Zacubo’s Efficacy and Safety in GERD Treatment

A study shows Onconic Therapeutics' Zacubo significantly improves GERD symptoms in patients unresponsive to existing treatments.

Fexuclue 40mg: How This New GERD Treatment is Revolutionizing Healthcare in Indonesia

Daewoong Pharmaceutical's Fexuclue receives approval in Indonesia for treating GERD, aiming for rapid expansion in the market.

Your Guide to Jaqbo: The New GERD Treatment Shaping the Future of Chronic Care

Onconic Therapeutics begins a Phase 3 trial for Jaqbo, aiming to expand GERD treatment options and enhance long-term management strategies.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

Top News

- Our Sponsors Ad -

Follow us